Gastroenterology Daily Report: 01/15/2024

A Phase 3 Randomized, Double-Blind, Noninferiority, Multicenter study investigated the effect of low-dose PPI (DW1903) and H2RA (DW1903R1) in 476 patients with endoscopic erosive gastritis (1). The study found that the erosion improvement rates were 59.8% for DW1903 and 58.8% for DW1903R1 according to the full-analysis set, and 61.9% and 59.6% respectively according to the per-protocol analysis. Secondary endpoints showed no significant differences between the two groups except for a higher hemorrhagic improvement rate in the DW1903 group with statistical tendency. The number of adverse events was similar in both groups. The study concluded that low-dose PPI (DW1903) was not inferior to H2RA (DW1903R1) for treating gastritis. (ClinicalTrials.gov Identifier: NCT05163756).

Reference

Kim JH, Jung HY, Yoo IK, Park SY, Kim JG, Sung JK, Jang JS, Cheon GJ, Kim KO, Kim TO, Lee ST, Cho KB, Chun HJ, Park JJ, Park MI, Jang JY, Jeon SW, Cho JW, Kang DH, Kim GH, Kim JJ, Kim SG, Kim N, Lee YC, Hong SJ, Kim HS, Lee S, Lee SW. Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study. Gut Liver. 2024 Jan 15;18(1):70-76. doi: 10.5009/gnl220446. Epub 2023 Jun 13. PMID: 37309193; PMCID: PMC10791492.